

72

Patent Application  
Attorney Docket No. PC25028A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 7th day of April, 2005.

By

(Signature of person mailing)

Janice Denison

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: John E. Hambor, et al. :

APPLICATION NO.: 10/813,805 : Examiner: To be assigned

FILING DATE: 03/30/2004 : Group Art Unit: 1636

TITLE: GROWTH AND DIFFERENTIATION OF :  
STEM CELLS

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: April 7<sup>th</sup>, 2005

Respectfully submitted,




Deborah A. Martin

Attorney for Applicant(s)

Reg. No. 44,222

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-1821



INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. PC25028A				SERIAL NO. 10/813,805					
				APPLICANT John E. Hambor, et al.									
				FILING DATE 03/30/2004				GROUP 1636					
<b>U.S. PATENT DOCUMENTS</b>													
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>													
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
		Fausto, N., et al., <i>Role of growth factors and cytokines in hepatic regeneration</i> , <u>FASEB</u> , Vol. 9(15): 1527-1536, 1995											
		Francavilla, A., et al., <i>Augmenter of liver regeneration: Its place in the universe of hepatic growth factors</i> , <u>Hepatology</u> , Vol. 20(3): 747-757, 1994											
		Hagiya, M., et al., <i>Cloning and sequence analysis of the rat augmenter of liver regeneration (ALR) gene: Expression of biologically active recombinant ALR and demonstration of tissue distribution</i> , <u>Proc. Natl. Acad. Sci.</u> , Vol. 91: 8142-8146, 1994 (erratum in <u>Proc. Natl. Acad. Sci.</u> , Vol. 92: 3076, 1995)											
		Li, Y., et al., <i>Stimulation of the mitogen-activated protein kinase cascade and tyrosine phosphorylation of the epidermal growth factor receptor by hepatopoietin</i> , <u>Journal of Biological Chem.</u> , Vol. 275(48): 37443-37447, 2000											
		Liskowsky, T., et al., <i>Mammalian augmenter of liver regeneration protein is a sulfhydryl oxidase</i> , <u>Dig. Liver Dis.</u> , Vol. 33: 173-180, 2001											
		Lu, C., et al., <i>Intracrine hepatopoietin potentiates AP-1 activity through JAB1 independent of MAPK pathway</i> , <u>FASEB J.</u> , Vol. 16(1): 90-92, 2002											
		Wang, G., et al., <i>Identification and characterization of receptor for mammalian hepatopoietin that is homologous to yeast ERV1</i> , <u>Journal of Biological Chem.</u> , Vol. 274(17): 11469-11472, 1999											
EXAMINER						DATE CONSIDERED							
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>													

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE